Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 3Phase NA 1Phase 3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Neoplasms, Plasma Cell 1Multiple Myeloma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia 1Hepatoblastoma 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Dexamethasone 169Bortezomib 92Lenalidomide 85daratumumab 44Thalidomide 44pomalidomide 43Melphalan 40Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14isatuximab 12Filgrastim 12ixazomib 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5iberdomide 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × Transplantation × Clear all
NCT01208662 2026-01-22

DFCI 10-106

Dana-Farber Cancer Institute

Phase 3 Active not recruiting
729 enrolled 29 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡